Unknown

Dataset Information

0

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients.

ABSTRACT: Adjuvant bisphosphonate therapy is increasingly used in postmenopausal breast cancer patients. This is based on level-one evidence that bisphosphonates, particularly zoledronic acid, can effectively prevent cancer treatment-induced bone loss in breast cancer patients receiving estradiol-lowering endocrine therapies such as aromatase inhibitors. Furthermore, emerging data from large clinical trials suggest that additional anticancer benefits can be derived due to a positive impact on the bone marrow microenvironment.

SUBMITTER: Gnant M 

PROVIDER: S-EPMC3132953 | biostudies-other | 2010

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients.

Gnant Michael M  

Breast care (Basel, Switzerland) 20101029 5

Adjuvant bisphosphonate therapy is increasingly used in postmenopausal breast cancer patients. This is based on level-one evidence that bisphosphonates, particularly zoledronic acid, can effectively prevent cancer treatment-induced bone loss in breast cancer patients receiving estradiol-lowering endocrine therapies such as aromatase inhibitors. Furthermore, emerging data from large clinical trials suggest that additional anticancer benefits can be derived due to a positive impact on the bone mar  ...[more]

Similar Datasets

Unknown Predicting the Benefit of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer Patients with Phosphorylated S6K1 Expression Status.
| S-EPMC7043945 | biostudies-literature
Unknown Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.
| S-EPMC3677838 | biostudies-literature
Unknown Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer.
| S-EPMC4969219 | biostudies-literature
Unknown Potential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancer.
| S-EPMC3529782 | biostudies-literature
Unknown Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.
| S-EPMC3201097 | biostudies-other
Unknown Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation.
| S-EPMC7930351 | biostudies-literature
Unknown Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy.
| S-EPMC4621696 | biostudies-other
Unknown Adjuvant therapy of triple negative breast cancer.
| S-EPMC3918886 | biostudies-literature
Unknown Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.
| S-EPMC4194305 | biostudies-literature
Unknown Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
| S-EPMC6777242 | biostudies-literature